{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:02:28Z","timestamp":1791093748686,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.ygyno.2011.05.004","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T20:10:49Z","timestamp":1309032649000},"page":"215-220","source":"Crossref","is-referenced-by-count":117,"title":["Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial"],"prefix":"10.1016","volume":"122","author":[{"given":"Marcello","family":"Deraco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Virz\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Macr\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Famulari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Solazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Rosario","family":"Iusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.05.004_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0010","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0140-6736(09)61338-6","article-title":"Ovarian cancer","volume":"374","author":"Hennessy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0020","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006014.pub5","article-title":"Interval debulking surgery for advanced epithelial ovarian cancer","author":"Tangjitgamol","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ygyno.2005.12.001","article-title":"The role of maintenance therapy and novel taxanes in ovarian cancer","volume":"102","author":"Herzog","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0040","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasm with pseudomyxoma peritonei syndrome","volume":"1","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0055","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.05.004_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jso.10255","article-title":"Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion","volume":"83","author":"Deraco","year":"2003","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2008-0275","article-title":"The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer","volume":"14","author":"Helm","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0070","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0080","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1048-891x.2004.14008.x","article-title":"Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum","volume":"14","author":"Look","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-7819-2-21","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer","volume":"2","author":"Piso","year":"2004","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0105","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2004.05.044","article-title":"Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer","volume":"94","author":"Ryu","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","article-title":"Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan","volume":"32","author":"Raspagliesi","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","article-title":"Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer","volume":"113","author":"Di Giorgio","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0120","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","article-title":"Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results","volume":"135","author":"Chua","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2008.12.022","article-title":"Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer. A critical need for an evidence-based evaluation","volume":"113","author":"Markman","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2006.07.045","article-title":"Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?","volume":"104","author":"Aletti","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jso.21388","article-title":"Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies","volume":"100","author":"Deraco","year":"2009","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/cncr.10176","article-title":"Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study","volume":"94","author":"Rossi","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0155","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jaquet","year":"1996","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0160","unstructured":"http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf"},{"issue":"9332","key":"10.1016\/j.ygyno.2011.05.004_bb0165","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"International Collaborative Ovarian Neoplasm Group","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2011.05.004_bb0170","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002800050870","article-title":"A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer","volume":"43","author":"Steller","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2006.07.004","article-title":"\u201cOptimal\u201d cytoreduction for advanced epithelial ovarian cancer: a commentary","volume":"103","author":"Eisenkop","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0180","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2011.05.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub2","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial EOC","author":"Jaaback","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"2 Suppl","key":"10.1016\/j.ygyno.2011.05.004_bb0190","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2008.11.005","article-title":"Advanced cytoreductive surgery in gynecologic oncology","volume":"114","author":"Bristow","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0195","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jnci\/djp151","article-title":"Intraperitoneal therapy for EOC: why has it not become standard?","volume":"101","author":"Rowan","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0200","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","article-title":"Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced EOC: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO","volume":"98","author":"Pfisterer","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0205","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1006\/gyno.2001.6312","article-title":"What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial EOC?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0210","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1200\/JCO.2005.02.1287","article-title":"Does aggressive surgery only benefit patients with less advanced EOC? Results from an international comparison within the SCOTROC-1 Trial","volume":"23","author":"Crawford","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0215","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/cncr.24317","article-title":"Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous EOC","volume":"115","author":"Adams","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0220","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0225","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","article-title":"Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality","volume":"249","author":"Chua","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ygyno.2011.05.004_bb0230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2009.03.011","article-title":"Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review","volume":"114","author":"Gerestein","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2011.05.004_bb0235","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2005.03.065","article-title":"Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study","volume":"23","author":"Gadducci","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2011.05.004_bb0240","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bjc.1995.539","article-title":"Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials","volume":"72","author":"Warwick","year":"1995","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2011.05.004_bb0245","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/gyno.2002.6750","article-title":"Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?","volume":"86","author":"Flynn","year":"2002","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811003581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811003581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T06:19:31Z","timestamp":1560320371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811003581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0090825811003581"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.05.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13198959.14541057","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}